Moderna, Inc. (MRNA) fundamentals score
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, it is reimagining how medicines are made to transform how it treats and prevent diseases. Since its founding, its mRNA platform has enabled the development of vaccine and therapeutic candidates across infectious disease, oncology, rare disease and more.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 3.5 out of 10, Weak long-term fundamentals
- Growth: 1.3/10
- Profitability: 1.1/10
- Financial health: 7.2/10
- Earnings quality: 7.8/10
- Valuation: 1.9/10
Scores are calculated from Moderna, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10